Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells

M R Smith1, T Xie, I Joshi

  • 1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.

British Journal of Haematology
|September 12, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pollinators support the nutrition and income of vulnerable communities.

Nature·2026
Same author

Correction to: MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.

Cell death & disease·2024
Same author

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

A phase Ib/II and pharmacokinetic study of EP0057 (formerly CRLX101) in combination with weekly paclitaxel in patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Gynecologic oncology·2021
Same author

Potential rise in iron deficiency due to future anthropogenic carbon dioxide emissions.

GeoHealth·2020
Same author

Global Health Implications of Nutrient Changes in Rice Under High Atmospheric Carbon Dioxide.

GeoHealth·2020
Same journal

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol.

British journal of haematology·2026
Same journal

Prospective, multicentre phase II study to evaluate the clinical benefit of reduced-dose lenalidomide and dexamethasone based on frailty stratification in elderly, unfit patients with newly diagnosed multiple myeloma.

British journal of haematology·2026
Same journal

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.

British journal of haematology·2026
Same journal

Novel germline GATA1s-generating variant associates with somatic STAG2 variants in hypoplastic myelodysplastic neoplasm.

British journal of haematology·2026
Same journal

The Endothelial Activation and Stress Index (EASIX) at diagnosis is associated with survival in primary central nervous system lymphoma.

British journal of haematology·2026
Same journal

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.

British journal of haematology·2026
See all related articles

Combining retinoic acid (RA) derivatives and dexamethasone (DEX) effectively inhibits multiple myeloma cell growth by reducing proliferation and increasing apoptosis. This dual-action therapy is more potent and less susceptible to resistance from Interleukin 6 (IL-6).

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Interleukin 6 (IL-6) is a critical growth factor for multiple myeloma.
  • Targeting IL-6 signaling pathways offers therapeutic potential for multiple myeloma.
  • Glucocorticoids and retinoic acid (RA) derivatives have shown promise in down-regulating IL-6 and IL-6 receptor (IL-6R) respectively.

Purpose of the Study:

  • To investigate the combined efficacy of RA derivatives and dexamethasone (DEX) in inhibiting multiple myeloma cell proliferation.
  • To explore the synergistic effects of RA and DEX on myeloma cell growth, apoptosis, and IL-6 signaling.
  • To determine if combined therapy is less susceptible to exogenous IL-6 compared to single agents.

Main Methods:

  • Treatment of myeloma cell lines (RPMI 8226 and U266B1) with various RA derivatives (ATRA, 13-cis-RA, 9-cis-RA) and DEX.

Related Experiment Videos

  • Assessment of cell proliferation, apoptosis induction, and IL-6 receptor (IL-6R) levels.
  • Measurement of IL-6 secretion and RNA levels in U266B1 cells.
  • Evaluation of the impact of exogenous IL-6 on the efficacy of combined RA + DEX treatment.

    • Main Results:

    • All tested RA derivatives inhibited RPMI 8226 myeloma cell growth, an effect enhanced by DEX.
    • RA primarily reduced the proliferative fraction and induced apoptosis, while DEX increased apoptosis.
    • Combined RA + DEX treatment showed enhanced apoptosis and reduced myeloma cell growth.
    • The combination therapy was least overcome by exogenous IL-6.
    • RA decreased IL-6R levels, and DEX addition delayed IL-6R recovery.
    • In U266B1 cells, RA and DEX reduced IL-6 secretion and RNA levels.
    • DEX enhanced RA-mediated IL-6R down-regulation, while both reduced IL-6 protein and RNA.

    Conclusions:

    • Combined RA and DEX therapy demonstrates superior efficacy in inhibiting multiple myeloma cell growth compared to single agents.
    • The dual mechanism of action involves decreasing the proliferative fraction and increasing apoptosis.
    • This combination therapy exhibits enhanced resistance to exogenous IL-6, suggesting a more robust therapeutic strategy.
    • The synergistic effects of RA and DEX on IL-6 signaling pathways warrant further investigation for multiple myeloma treatment.